{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Large+Cell+Neuroendocrine+Carcinoma&page=2", "query": { "condition": "Cervical Large Cell Neuroendocrine Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Large+Cell+Neuroendocrine+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T16:42:45.496Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06814496", "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Medullary Thyroid Cancer", "Sinonasal Undifferentiated Carcinoma", "Esthesioneuroblastoma", "Bladder Cancer", "Testicular Cancer", "Glioblastoma Multiforme", "Cervical Cancer", "Large Cell Neuroendocrine Carcinoma of the Lung", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "Tarlatamab", "type": "DRUG" }, { "name": "Concurrent Radiation Therapy", "type": "RADIATION" }, { "name": "Sequential Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2025-09-08", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 2, "location_summary": "Tucson, Arizona • Seattle, Washington", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06814496" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT04907643", "title": "Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Pain", "Visceral Pain", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Small Intestine Cancer", "Pancreas Cancer", "Liver Cancer", "Colon Cancer", "Biliary Tract Cancer", "Stomach Cancer", "Rectum Cancer", "Peritoneal Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Cancers - Anus", "Gastrointestinal Cancers - Stomach", "Gastrointestinal Cancers - Colorectal", "Gastrointestinal Cancers - Small Intestine", "Small Intestine Cancer Stage III", "Small Intestine Cancer Stage IV", "Small Intestine Cancer, Recurrent", "Pancreas Cancer, Stage III", "Pancreas Cancer, Stage IV", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Liver Cancer Stage IIIa", "Liver Cancer Stage IIIb", "Liver Cancer Stage IIIc", "Liver Cancer Stage IV", "Colon Cancer Stage III", "Colon Cancer Stage IV", "Stomach Cancer Stage III", "Stomach Cancer Stage IV", "Stomach Cancer Recurrent", "Rectum Cancer, Recurrent", "Gastrointestinal Cancers - Liver", "Anal Cancer", "Anal Cancer Stage III", "Anal Cancer Stage IV", "Anal Cancer Recurrent", "Anal Cancer Metastatic", "Anal Cancer, Stage IIIA", "Anal Cancer, Stage IIIB", "Appendix Cancer", "Ampullary Cancer", "Bile Duct Cancer", "Bile Duct Cancer Stage III", "Bile Duct Cancer Stage IV", "Bile Duct Cancer Stage IVA", "Bile Duct Cancer Stage IVB", "Bile Duct Cancer Recurrent", "Carcinoid Tumor", "Carcinoid Tumor of Pancreas", "Carcinoid Tumor of Large Intestine", "Carcinoid Tumor of GI System", "Carcinoid Tumor of Colon", "Carcinoid Tumor of Liver", "Carcinoid Tumor of Cecum", "Carcinoid Tumor of Ileum", "Carcinoid Tumor of Rectum", "Carcinoid Tumor of the Small Bowel", "Carcinoid Tumor of the Stomach", "Large Intestine Cancer", "Esophagus Cancer", "Esophagus Cancer, Stage III", "Esophagus Cancer, Stage IV", "Esophagus Cancer, Recurrent", "Gallbladder Cancer", "Gallbladder Cancer Stage III", "Gallbladder Cancer Stage IV", "Gastric (Stomach) Cancer", "Neuroendocrine Tumor", "Peritoneum Cancer", "Rectal Cancer", "Esophagus Cancer, Stage I", "Esophagus Cancer, Stage II", "Gallbladder Cancer Stage I", "Gallbladder Cancer Stage II", "Bile Duct Cancer Stage I", "Bile Duct Cancer Stage II" ], "interventions": [ { "name": "PICO G2 4k", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 360, "start_date": "2021-10-05", "completion_date": "2027-03-16", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04907643" }, { "nct_id": "NCT06022029", "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Lymphoma, Non-Hodgkin", "Mantle Cell Lymphoma", "Bladder Cancer", "Uveal Melanoma, Recurrent", "Cervix Cancer", "Carcinoma in Situ", "Head and Neck Squamous Cell Carcinoma", "Skin Cancer", "Metastatic Cancer", "Tumor, Solid", "Tumor Recurrence" ], "interventions": [ { "name": "ONM-501", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoNano Medicine, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2023-10-13", "completion_date": "2026-08-29", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 9, "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tamarac", "state": "Florida" }, { "city": "Canton", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06022029" }, { "nct_id": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Carcinoma (NSCLC)", "Renal Cell Carcinoma (RCC)", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Cancer", "Classical Hodgkin Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Urothelial Carcinoma", "Microsatellite Instability-High Cancer", "Gastric Cancer", "Esophageal Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Brain Metastases, Adult" ], "interventions": [ { "name": "LITT + Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2020-01-10", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 2, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04187872" }, { "nct_id": "NCT04772989", "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer (NSCLC)", "Melanoma", "Cervical Cancer", "Multiple Myeloma", "Lymphoma, Non-Hodgkin", "Diffuse Large B Cell Lymphoma (DLBCL)", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "AB308", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2021-03-19", "completion_date": "2025-08-25", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 15, "location_summary": "Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772989" }, { "nct_id": "NCT06870487", "title": "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peripheral T Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Classical Hodgkin Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "PF-08046032", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2025-05-08", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 3, "location_summary": "San Antonio, Texas • Seattle, Washington", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06870487" }, { "nct_id": "NCT00002947", "title": "Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Langerhans Cell Histiocytosis", "Gastrointestinal Carcinoid Tumor", "Head and Neck Cancer", "Intraocular Melanoma", "Islet Cell Tumor", "Kidney Cancer", "Lung Cancer", "Melanoma (Skin)", "Neoplastic Syndrome", "Neuroendocrine Carcinoma of the Skin", "Pheochromocytoma" ], "interventions": [ { "name": "indium In 111 pentetreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "1996-10", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2014-07-02", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002947" }, { "nct_id": "NCT03538028", "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Microsatellite Instability (MSI)-High Endometrial Cancer", "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma (Uveal Melanoma Excluded)", "Merkel Cell Carcinoma", "Mesothelioma", "MSI-high Colorectal Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Small Cell Lung Cancer (SCLC)", "Renal Cell Carcinoma (RCC)", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "INCAGN02385", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-06-18", "completion_date": "2020-10-07", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 4, "location_summary": "Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538028" }, { "nct_id": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cholangiocarcinoma", "Colorectal Cancer", "Head and Neck Neoplasms", "Lymphoma, Large-Cell, Anaplastic", "Melanoma", "Neuroendocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Papillary Thyroid Cancer", "Primary Brain Tumors", "Renal Cell Carcinoma", "Sarcomas", "Salivary Gland Cancers", "Adult Solid Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2015-11-19", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-10T16:42:45.496Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568267" } ] }